Stoke Therapeutics, Inc.
NASDAQ:STOKBiotechnology
-$0.34 today
- Market cap
- $1.75B
- Beta
- 1.19
- P/E (TTM)
- -11.1
- EPS (TTM)
- -$2.69
Volume 0.76M
Average 0.64M
STOK Investing Cash Flow
Net cash used in or generated by investments in assets, acquisitions, and securities.
Stoke Therapeutics, Inc.NASDAQ: STOK
Investing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Investing cash flow growth accelerates
Q1 FY2026 investing cash flow of $50.69M rose 271.9% year over year, ahead of the +44.2% change in trailing-twelve-month investing cash flow. Over 3 fiscal years it compounded at +59.7% a year.
Context
- Investing cash flow amounted to 101.3% of revenue in FY2025, down 192.7 pp from a year earlier.
- Investing cash flow increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +271.9% holds above the trailing-twelve-month pace of +44.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Investing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (186.81M) USD
- Year-over-year change
- -73.8%
| Period | Period end | Investing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (186.81M) | -73.8% |
| FY2024 | 2024-12-31 | (107.48M) | -201.4% |
| FY2023 | 2023-12-31 | 105.95M | +330.9% |
| FY2022 | 2022-12-31 | (45.88M) | +40.0% |
| FY2021 | 2021-12-31 | (76.43M) | — |
Investing Cash Flow vs competitors
How STOK compares with its peers on the latest reported figures
- Peers report in different currencies, so investing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +44.2% is the 2nd highest of 6, against a peer median of +14.6%.
- Investing cash flow amounts to 466.8% of revenue for STOK, versus a peer median of 25.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $240.69M USD | +14.6% | +1.9% | 25.1% | |
| LTM Jun 2026 | $189.46M USD | +231.1% | -35.9% | 121.4% | |
| LTM Mar 2026 | $149.75M USD | +44.2% | +59.7% | 466.8% | |
| LTM Mar 2026 | $7.45M USD | -76.1% | — | — | |
| LTM Mar 2026 | $6.39M USD | — | +32.8% | 693.3% | |
| LTM Mar 2026 | $981.99K USD | +43.1% | -17.0% | 1.4% | |
| LTM Mar 2026 | €955.79K EUR | -107.1% | +11.8% | 7.1% | |
| Peer median (excluding STOK) | — | +14.6% | +1.9% | 25.1% | |
Competitors are the stored peer set for STOK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (85.81M) | (101.07M) | (104.7M) | (88.98M) | (6.89M) |
| Depreciation & Amortization | 974K | 1.55M | 2.47M | 2.18M | 1.77M |
| Deferred Income Tax | 172K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 16.45M | 22.85M | 25.26M | 27.47M | 32.24M |
| Change in Working Capital | 46K | 43.02M | (6.03M) | (28.14M) | 16.35M |
| Accounts Receivables | 0 | 0 | 0 | 0 | (4.27M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 2.9M | 121K | (3.21M) | 3.09M | 21.29M |
| Other Working Capital | (2.85M) | 42.9M | (2.82M) | (31.23M) | (675K) |
| Other Non-Cash Items | 1.26M | 1.78M | 1.94M | 623K | 2.12M |
| Operating Cash Flow | (66.91M) | (31.87M) | (81.07M) | (86.85M) | 45.59M |
| Capital Expenditures | (1.2M) | (3.96M) | (1.62M) | (203K) | (670K) |
| Acquisitions (Net) | 75.23M | 45.34M | 0 | 0 | 0 |
| Purchases of Investments | (87.23M) | (201.32M) | 0 | (167.27M) | (322.72M) |
| Sales of Investments | 12M | 159.4M | 107.56M | 60M | 136.58M |
| Other Investing Activities | (75.23M) | (45.34M) | 0 | 0 | 0 |
| Investing Cash Flow | (76.43M) | (45.88M) | 105.95M | (107.48M) | (186.81M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 1.29M | 45.34M | 52.08M | 128.84M | 97.39M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (2K) | 1.07M | 926K | 2.25M | 0 |
| Financing Cash Flow | 1.28M | 46.41M | 53.01M | 131.09M | 97.39M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (142.05M) | (31.34M) | 77.89M | (63.23M) | (43.84M) |
| Free Cash Flow | (68.11M) | (35.83M) | (82.68M) | (87.05M) | 44.92M |
Stoke Therapeutics, Inc.
NASDAQ:STOK
Intrinsic Alpha fair value
Locked
Current Price
$26.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.